Carcinoma, Neuroendocrine: all 238 studies
Page 3 of 3. Open to participants first (65), then studies with results posted, then the rest; newest registration first within each.
- Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II StudyCompletedNCT02113800Phase 2
- 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine TumorsStatus unknownNCT02038738Phase 1/2
- Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine CarcinomasWithdrawnNCT02030184Phase 1/2
- Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid CancerCompletedNCT01945762
- Radiolabeled Molecules for Medullary Thyroid CancerStatus unknownNCT01915485Phase 4
- 68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)CompletedNCT01879657Not applicable
- A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine TumoursSuspendedNCT01876771Phase 2
- Clinical Trial of the Impact of Treatment Consultation Recordings on Cancer Patient OutcomesCompletedNCT01866228Not applicable
- Nintedanib(BIBF1120) in Thyroid CancerCompletedNCT01788982Phase 2
- The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid CancerStatus unknownNCT01739634Phase 1/2
- Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid CarcinomaWithdrawnNCT01736878Phase 2
- ImmunoTEP for Patients With Medullary Thyroid Carcinoma.CompletedNCT01730638Phase 1/2
- Role of Perfusion CT in Pancreatic CancerStatus unknownNCT01703650
- Expanded Access of Cabozantinib in Medullary Thyroid CancerApproved for marketingNCT01683110
- SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid CancerCompletedNCT01625520Phase 2
- Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine TumorsCompletedNCT01603004
- Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals PatientsCompletedNCT01424878
- Evaluation of Methods for the Determination of Chromogranin A in Routine Blood SamplesCompletedNCT01216267Not applicable
- Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine CarcinomaCompletedNCT01204476Phase 1
- Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine TumorsStatus unknownNCT01203306Phase 2
- Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid TumorsCompletedNCT01155258Phase 1
- A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced CancersCompletedNCT00926640Phase 1
- Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine CarcinomaCompletedNCT00780663Phase 2
- Study Investigating MEN1 and SDHD in Familial Carcinoid TumorsStatus unknownNCT00672269
- Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine CarcinomaCompletedNCT00663429Phase 2
- Everolimus and Vatalanib in Treating Patients With Advanced Solid TumorsCompletedNCT00655655Phase 1
- Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.CompletedNCT00423254Phase 1
- Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine CarcinomaCompletedNCT00388063Phase 2
- Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal TractCompletedNCT00353015Phase 2
- Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine CarcinomaCompletedNCT00193531Phase 2
- Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic TumorsStatus unknownNCT00178698Phase 2
- Oblimersen in Treating Patients With Merkel Cell CarcinomaCompletedNCT00079131Phase 2
- S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell CancerCompletedNCT00068783Phase 2
- Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver MetastasesCompletedNCT00019786Phase 2
- Irinotecan in Treating Patients With Advanced Neuroendocrine TumorsCompletedNCT00004922Phase 2
- S9716: Combination Chemotherapy in Treating Patients With Merkel Cell CancerCompletedNCT00003549Phase 2
- Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation TherapyWithdrawnNCT00003514Phase 2
- Indium In 111 Pentetreotide in Treating Patients With Refractory CancerTerminatedNCT00002947Phase 1